Safety and efficacy of the biologic response modifiers.
Markenson
Joseph
J
Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA.
D018951:Antigens, CD20 / Q000187:drug effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018951:Antigens, CD20; D007155:Immunologic Factors; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha